This phase II/III trials studies whether maintenance immunotherapy (Nivolumab) following definitive treatment with radiation and chemotherapy (Cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue or lymph nodes.
